Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rick Turner

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Journal of Clinical Pharmacology|November 20, 2019
How to Prescribe Drugs With an Identified Proarrhythmic LiabilityMunveer Thind, Ignacio Rodriguez, Sam Kosari, et al.
The International Journal of Pharmacy Practice|September 29, 2016
Clinical pharmacists' opportunities to reduce inappropriate prescription of QT-prolonging medications: calls to actionTrusha C Dhanani, Emily H Mantovani, J Rick Turner
Therapeutic Innovation & Regulatory Science|September 19, 2018
Bowel Preparations for Colonoscopy: A Regulatory PerspectiveKlaus Gottlieb, J Rick Turner, Barbara S Gillespie, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|April 23, 2014
Participation of hypertension patients in early-phase clinical trialsPaul Borron, Oren Cohen, Theo J Hoofwijk, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 23, 2014
Healthcare transition from pediatric to adult medical homes in diabetes mellitusJ Rick Turner, Desmond A Schatz, Kenneth Cusi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 1, 2017
Recent developments in the science of proarrhythmic cardiac safety of new drugsJ Rick Turner, Dilip R Karnad, Christopher H Cabell, et al.
American Heart Journal|March 1, 2014
Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research ConsortiumPhilip T Sager, Gary Gintant, J Rick Turner, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 24, 2016
With regard to the paper by Zannad et al. entitled Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversionJ Rick Turner, Dilip R Karnad, Snehal Kothari, et al.
Journal of Clinical Pharmacology|May 19, 2018
Individual-Specific QT Interval Correction for Drugs With Substantial Heart Rate Effect Using Holter ECGs Extracted Over a Wide Range of Heart RatesGopi Krishna Panicker, Pramod Kadam, Saikat Chakraborty, et al.
Diabetes Care|September 26, 2015
Alternate approaches for pediatric type 1 diabetes drug development and potential regulatory approval: a perspectiveJ Rick Turner, Kelly L Close, G Alexander Fleming, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Journal of Clinical Pharmacology|November 20, 2019
How to Prescribe Drugs With an Identified Proarrhythmic LiabilityMunveer Thind, Ignacio Rodriguez, Sam Kosari, et al.
The International Journal of Pharmacy Practice|September 29, 2016
Clinical pharmacists' opportunities to reduce inappropriate prescription of QT-prolonging medications: calls to actionTrusha C Dhanani, Emily H Mantovani, J Rick Turner
Therapeutic Innovation & Regulatory Science|September 19, 2018
Bowel Preparations for Colonoscopy: A Regulatory PerspectiveKlaus Gottlieb, J Rick Turner, Barbara S Gillespie, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|April 23, 2014
Participation of hypertension patients in early-phase clinical trialsPaul Borron, Oren Cohen, Theo J Hoofwijk, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 23, 2014
Healthcare transition from pediatric to adult medical homes in diabetes mellitusJ Rick Turner, Desmond A Schatz, Kenneth Cusi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 1, 2017
Recent developments in the science of proarrhythmic cardiac safety of new drugsJ Rick Turner, Dilip R Karnad, Christopher H Cabell, et al.
American Heart Journal|March 1, 2014
Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research ConsortiumPhilip T Sager, Gary Gintant, J Rick Turner, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 24, 2016
With regard to the paper by Zannad et al. entitled Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversionJ Rick Turner, Dilip R Karnad, Snehal Kothari, et al.
Journal of Clinical Pharmacology|May 19, 2018
Individual-Specific QT Interval Correction for Drugs With Substantial Heart Rate Effect Using Holter ECGs Extracted Over a Wide Range of Heart RatesGopi Krishna Panicker, Pramod Kadam, Saikat Chakraborty, et al.
Diabetes Care|September 26, 2015
Alternate approaches for pediatric type 1 diabetes drug development and potential regulatory approval: a perspectiveJ Rick Turner, Kelly L Close, G Alexander Fleming, et al.
Pageof 7